In follow‐up metagenomics analysis studies to further prospectively validate the predictive value of fecal Akk, Akk relative abundance may be a predictor of objective response in advanced NSCLC patients receiving first‐ and second‐line ICI therapy and beyond 12 months biomarkers of survival, in multivariate analysis, baseline fecal Akk was associated with increased objective response rate and overall survival independent of PD‐L1 expression, antibiotics and performance status.18 The gene discussed is CD274; the disease is non-small cell lung carcinoma.